Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Benzinga · 1d ago
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.